Jiangsu Alphamab Biopharmaceuticals
As of the edition of 20 October 2026, Jiangsu Alphamab Biopharmaceuticals runs 15 drugs; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 12 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 15 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Jiangsu Alphamab Biopharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 19 trials led
- Skin and connective tissue: 9 trials led
- Lungs and airways: 3 trials led